Ivabradine Amarox

Ivabradine, the active ingredient in Ivabradine Amarox, is a If channel inhibitor presented as an oral tablet for oral use. It is employed in the management of chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients. It is indicated for patients who require heart‑rate reduction without negative inotropic effects.

GNH USA supplies Ivabradine Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Ivabradine is used to manage conditions related to cardiac ischemia and heart failure by reducing heart rate. - Chronic stable angina pectoris: reduces frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, improving symptoms and decreasing hospitalization risk. - Stable angina: helps control chest pain by maintaining a lower heart rate.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below the intended therapeutic range. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness. - Fatigue: reduced energy levels. - Blurred vision: temporary visual acuity changes.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Severe hypotension leading to syncope. - Persistent visual impairment or retinal toxicity.

Before initiating ivabradine, consider the following precautions. - Hepatic impairment: adjust dose in severe liver disease. - Baseline heart rate: ensure resting heart rate is ≥60 bpm before starting. - Sick sinus syndrome: avoid use in patients with this condition. - Concomitant bradycardic agents: monitor closely when combined with beta‑blockers or calcium‑channel blockers. - Hypotension: use caution in patients with low blood pressure. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Verapamil or diltiazem: may modestly increase ivabradine exposure. - Amiodarone: potential additive effect on heart rate. - QT‑prolonging drugs: monitor ECG for interval changes.